ES2171156T3 - Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas. - Google Patents

Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas.

Info

Publication number
ES2171156T3
ES2171156T3 ES90914669T ES90914669T ES2171156T3 ES 2171156 T3 ES2171156 T3 ES 2171156T3 ES 90914669 T ES90914669 T ES 90914669T ES 90914669 T ES90914669 T ES 90914669T ES 2171156 T3 ES2171156 T3 ES 2171156T3
Authority
ES
Spain
Prior art keywords
genetic engineering
aids
retrovirical
diseases
vaccine production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90914669T
Other languages
English (en)
Inventor
Joel Haynes
Michel Henri Klein
Benjamin Rovinski
Shi Xian Cao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur Ltd
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd, Aventis Pasteur SA filed Critical Aventis Pasteur Ltd
Application granted granted Critical
Publication of ES2171156T3 publication Critical patent/ES2171156T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA PARTICULA, TIPO-RETROVIRUS, INMUNOGENICA QUE NO ES INFECCIOSA Y QUE ES UTIL COMO COMPONENTE CANDIDATO A UNA VACUNA PARA LAS INFECCIONES RETROVIRALES, INCLUYENDO EL SIDA Y ATLL, SE PRODUCE MEDIANTE INGENIERIA GENETICA.
ES90914669T 1989-10-13 1990-10-12 Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas. Expired - Lifetime ES2171156T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898923123A GB8923123D0 (en) 1989-10-13 1989-10-13 A vaccine for human immunodeficiency virus

Publications (1)

Publication Number Publication Date
ES2171156T3 true ES2171156T3 (es) 2002-09-01

Family

ID=10664542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90914669T Expired - Lifetime ES2171156T3 (es) 1989-10-13 1990-10-12 Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas.

Country Status (10)

Country Link
US (5) US5439809A (es)
EP (1) EP0495811B1 (es)
JP (1) JP2537570B2 (es)
AT (1) ATE211766T1 (es)
CA (1) CA2067333C (es)
DE (1) DE69033896T2 (es)
DK (1) DK0495811T3 (es)
ES (1) ES2171156T3 (es)
GB (1) GB8923123D0 (es)
WO (1) WO1991005864A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
ZA909302B (en) * 1989-11-20 1991-09-25 Oncogen Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for prophylaxis and therapy against human retroviruses
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
US5866137A (en) * 1990-10-12 1999-02-02 Benjamin Rovinski Self-assembled, non-infectious, non-replicating; immunogenic retrovirus-like particles comprising modified HIV genomes devoid of long terminal repeats and chimeric envelope glycoproteins
AU702634B2 (en) * 1991-03-07 1999-02-25 Virogenetics Corporation Immunodeficiency recombinant poxvirus
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
JPH07500490A (ja) * 1991-05-15 1995-01-19 ランスティチュ　ドュ　レシェルシュ　クリニーク　ドュ　モントリオール 非感染性ｈｉｖゲノムを保持するトランスジェニック非ヒト動物
US6268211B1 (en) 1991-08-20 2001-07-31 L'institut De Recherches Cliniques De Montreal Non-infectious HIV transgene
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
DE69430646T2 (de) * 1993-02-17 2003-01-02 Wisconsin Alumni Research Foundation, Madison Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
US5470572A (en) * 1993-07-16 1995-11-28 University Of Puerto Rico Non-infectious simian immunodeficiency virus particles produced by cell line CRL 11393
WO1995005851A1 (en) * 1993-08-20 1995-03-02 St. Luke's-Roosevelt Hospital Center HIV vif-RELATED COMPOSITIONS, AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF
US6015661A (en) * 1994-02-14 2000-01-18 The Macfarlane Burnet Centre For Medical Research Limited Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US5858838A (en) 1998-02-23 1999-01-12 Taiwan Semiconductor Manufacturing Company, Ltd. Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
WO1996014855A1 (en) * 1994-11-15 1996-05-23 Agracetus, Inc. Method for inducing humoral and cellular immune responses utilizing intracellular delivery of peptide-coated microparticles
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
IL125464A (en) * 1996-01-29 2007-12-03 Virologic Inc Preparations and methods for determining susceptibility and resistance to antiviral drugs and filtering antiviral drugs
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6024965A (en) * 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
WO1998043669A1 (en) * 1997-04-03 1998-10-08 Thomas Jefferson University Chimeric viral proteins
KR100314142B1 (ko) * 1997-08-07 2002-06-22 김기태 재조합사빈1형폴리오바이러스벡터
US20050033022A1 (en) * 1997-09-26 2005-02-10 Smithkline Beecham Biologicals Sa Fusion proteins comprising HIV-1 Tat and/or Nef proteins
US6121021A (en) 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
FI105105B (fi) * 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
WO1999058726A1 (en) 1998-05-12 1999-11-18 Genecure Llc Replication defective hiv vaccine
US7090848B1 (en) * 1998-08-04 2006-08-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
WO2000007631A1 (en) * 1998-08-04 2000-02-17 The Henry M. Jackson Foundation Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
US6764676B1 (en) 1998-08-24 2004-07-20 Pfizer Inc. Compositions and methods for protecting animals from lentivirus-associated disease such as feline immunodeficiency virus
EP1418940A4 (en) 2000-03-02 2006-09-20 Univ Emory DNA EXPRESSION VECTORS AND METHODS OF USE
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
DK1280551T3 (da) * 2000-04-27 2007-05-21 Sanofi Pasteur Ltd Vacciner mod HIV-infektion
EP1776961A1 (en) * 2000-04-27 2007-04-25 Sanofi Pasteur Limited Immunizing against HIV infection
US6585978B1 (en) * 2000-09-09 2003-07-01 Akzo Nobel EIA vaccine and diagnostic
US6461616B1 (en) * 2000-09-09 2002-10-08 Akzo Nobel Nv EIAV p26 deletion vaccine and diagnostic
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
PT1372710E (pt) * 2001-03-08 2009-12-21 Us Gov Health & Human Serv Vam modificado que expressa os genes gag e pol do envelope de vih
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c
US7943146B2 (en) * 2001-12-21 2011-05-17 Myrexis, Inc. Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface
WO2004065575A2 (en) * 2003-01-15 2004-08-05 Research Institute For Genetic And Human Therapy (Right) Dna compositon and uses thereof
AU2004270275B2 (en) * 2003-09-09 2010-02-18 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to HIV humans
US20050222068A1 (en) 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US20090239215A1 (en) * 2004-12-16 2009-09-24 Brandeis University Clonable Tag for Purification and Electron Microscopy Labeling
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2009049351A1 (en) * 2007-10-15 2009-04-23 The University Of Queensland Construct system and uses therefor
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
AU2009335740B2 (en) 2008-12-17 2016-04-21 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
BR112013025481B8 (pt) 2011-04-06 2022-11-08 Univ Paris Descartes Composições farmacêuticas, uso destas e kits para prevenir e/ou tratar uma doença por hiv em humanos
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9249191B2 (en) 2012-02-16 2016-02-02 Vlp Therapeutics, Llc Virus like particle composition
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US9730996B2 (en) * 2012-10-24 2017-08-15 Texas Biomedical Research Institute Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
MX383330B (es) 2014-09-11 2025-03-13 Vlp Therapeutics Inc Particula tipo virus de flavivirus.
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3386593A4 (en) 2015-12-09 2019-07-24 Admedus Vaccines Pty Ltd IMMUNOMODULATING COMPOSITION FOR TREATMENT
CN120607606A (zh) 2017-08-22 2025-09-09 莫纳施大学 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节
CA3074088A1 (en) * 2017-09-01 2019-03-07 Inprother Aps A vaccine for use in the prophylaxis and/or treatment of a disease
KR102823029B1 (ko) 2017-12-20 2025-06-20 브이엘피 테라퓨틱스 인코포레이티드 알파바이러스 레플리콘 입자
WO2020257309A1 (en) * 2019-06-17 2020-12-24 Enochian BioPharma, Inc. Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity
EP4135847A4 (en) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus vaccine
CN115552009A (zh) 2020-04-30 2022-12-30 Vlp治疗公司 细胞因子免疫疗法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59104325A (ja) * 1982-12-07 1984-06-16 Japan Found Cancer ヒト白血病ウイルスの遺伝子ｒｎａに相補性を示すｄｎａ
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
ZA867281B (en) * 1985-09-25 1987-05-27 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4752565A (en) * 1986-04-07 1988-06-21 The United States Of America As Represented By The Department Of Health And Human Services Cell line producing AIDS viral antigens without producing infectious virus particles
EP0329671B1 (en) * 1986-11-01 1994-01-12 British Bio-Technology Limited Particulate hybrid hiv antigens
JPH01120284A (ja) * 1987-11-05 1989-05-12 Shiro Kato Ｈｉｖ不完全粒子および該製造方法
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5019752A (en) 1988-06-16 1991-05-28 Hughes Aircraft Company Plasma switch with chrome, perturbated cold cathode
JPH02203783A (ja) * 1989-02-02 1990-08-13 Banyu Pharmaceut Co Ltd 抗原性を有する非感染性エイズウイルス産生クローン化ヒトｔ細胞
JP3140757B2 (ja) * 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
WO1990015141A2 (en) * 1989-06-01 1990-12-13 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
JP2897295B2 (ja) * 1989-12-14 1999-05-31 味の素株式会社 レトロウィルス高生産用ｄｎａ構築物及びレトロウィルス高生産用細胞株
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles

Also Published As

Publication number Publication date
ATE211766T1 (de) 2002-01-15
EP0495811A1 (en) 1992-07-29
US5439809A (en) 1995-08-08
JPH04506301A (ja) 1992-11-05
US5571712A (en) 1996-11-05
JP2537570B2 (ja) 1996-09-25
US6291227B1 (en) 2001-09-18
DK0495811T3 (da) 2002-02-11
DE69033896D1 (de) 2002-02-14
CA2067333A1 (en) 1991-04-14
WO1991005864A1 (en) 1991-05-02
GB8923123D0 (en) 1989-11-29
US5985641A (en) 1999-11-16
EP0495811B1 (en) 2002-01-09
DE69033896T2 (de) 2002-11-14
US7008784B1 (en) 2006-03-07
CA2067333C (en) 2001-05-01

Similar Documents

Publication Publication Date Title
ES2171156T3 (es) Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas.
KR900013082A (ko) Pf1022 물질, 그 생산방법 및 그 물질을 포함한 구충제 조성물
PT626998E (pt) "producao de plantas resistentes aos virus, mediante introducao de uma molecula de arn viral nao traduzivel e de sentido codificador"
MX9304027A (es) Variante de al enzima lipasa y metodo para su produccion.
DOP1960000898A (es) Metodo para hace hojas de rasurar.
CY1113241T1 (el) Μεθοδος για την παραγωγη ενεργου συστατικου ενος φαρμακευτικου ή διαγνωστικου μεσου εντος καλλιεργειας αιωρηματος κυτταρων mdck
DK489686D0 (da) Fremgangsmaade til fremstilling af 2-keto-l-gulonsyre
IT8320982A0 (it) Sospensione acquosa di combustibile solido, e processo per la suaproduzione.
ES2057191T3 (es) Metodo de produccion para una composicion que contiene proteinas.
ES2042751T3 (es) Nuevo procedimiento para la purificacion de viriones de la hepatitis a.
YU99090A (sh) Postupak za dobijanje novih sojeva s. avermitilis
DE69230180D1 (de) Neuartige hefestämme zur herstellung von xylitol
ES2056048T3 (es) Proceso mejorado para agentes antibacterianos de acido quinolein-3-carboxilico.
YU391A (sh) Biomasa za proizvodnju virusa/virusantigena
PT81647B (pt) Processo para a obtencao da enzima lenhinolitica por cultura de microorganismos da estirpe phanerochaete chrysosporium
ES2058343T3 (es) Piridinas disubstituidas.
ES2055238T3 (es) Procedimiento para producir esteres de acido alfa-ceto-carboxilico.
ES464357A1 (es) Procedimiento para la produccion de una composicion de ce- mento hidraulico
PT81970B (pt) Processo para a preparacao de um reagente para a dosagem, por hemaglutinacao, de anticorpos contra as toxinas bacterianas
ES2054755T3 (es) Un proceso para la produccion de 2,4,5-trifluoroisoftalonitrilo.
IT964372B (it) Processo per la produzione di sesquiterpeni
ES2059373T3 (es) Extractos de la especie nerium, sus procedimientos de fabricacion y su utilizacion.
DK0592685T3 (da) Plante, som er resistent over for to eller flere vira, og fremstilling deraf
BR7807290A (pt) Plasmideo,processo para producao de um polipeptido especifico veiculo clonal,cultura bacteriana transformante,processo para produzir uma substancia imunogenica processo para preparar um gene estrutural,e polidesoxirribonucleotido de faixa dupla
ES2074257T3 (es) Derivados de aminoacidos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 495811

Country of ref document: ES